Furosemide
- Generic Name
- Furosemide
- Brand Names
- Furoscix, Lasix
- Drug Type
- Small Molecule
- Chemical Formula
- C12H11ClN2O5S
- CAS Number
- 54-31-9
- Unique Ingredient Identifier
- 7LXU5N7ZO5
- Background
Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrol...
- Indication
Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.
...
- Associated Conditions
- Acute Pulmonary Edema, Ascites, Body Fluid Retention, Edema, Hypertension, Mild to Moderate Hypertension, Chest congestion
- Associated Therapies
- -
FDA grants Tentative Approval of SQ Innovation's Lasix® ONYU
Gerresheimer announces FDA Tentative Approval for Lasix ONYU, a furosemide and on-body device combo for fluid overload in heart failure, with full approval expected post-2025 exclusivity period. The device, designed for patient comfort and environmental sustainability, aims to reduce healthcare costs and improve quality of life through home treatment.
Gerresheimer: FDA grants Tentative Approval of SQ Innovation's Lasix® ONYU
Gerresheimer announces FDA Tentative Approval for SQ Innovation's Lasix ONYU, a combination of furosemide and an on-body device for fluid overload treatment. The device, designed by Gerresheimer, uses micropump technology for precise drug administration. Tentative Approval indicates meeting U.S. regulatory standards, with full approval expected post-2025 due to market exclusivity of a competing product. Lasix ONYU aims to improve patient quality of life and reduce healthcare costs.
scPharmaceuticals Inc. SEC 10-Q Report
scPharmaceuticals Inc. reported $10.0 million in product revenues, a net loss of $(35.1) million, and a loss from operations of $(18.1) million for Q3 2024. The company is focused on optimizing infused therapies, with FUROSCIX expanding to NYHA Class IV heart failure and a new autoinjector in development. The FDA awarded 3-year exclusivity to FUROSCIX, and the company estimates a $12.5 billion market for the product. The company expects continued net losses and is managing capital through various agreements and offerings.
Congestive Heart Failure Treatment Market 2034: Clinical
DelveInsight's report on Congestive Heart Failure Market (2020-2034) covers epidemiology, market trends, key companies, and therapies. Market size was ~USD 6,900 million in 2023, expected to grow significantly. Key companies include Novartis, Bayer, and Eli Lilly. Therapies like ENTRESTO and JARDIANCE are highlighted. Market drivers include aging population and disease prevalence, while barriers include generic therapies and diagnostic challenges.
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix Indication in Heart Failure
scPharmaceuticals announces FDA approval of sNDA expanding Furoscix indication in heart failure, now including NYHA Class IV patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath